Oral immunotherapy for peanut allergy: The pro argument

Area of Science:

• Immunology
• Allergy and Immunology
• Public Health

Background:

• Food allergy (FA) affects 8% of children and 10.8% of adults in the US, posing significant health and economic challenges.
• Peanut allergies are persistent, often lasting into adulthood, unlike milk or egg allergies.
• Current FA management relies on dietary avoidance and symptom treatment, which is often challenging and can lead to severe reactions.

Purpose of the Study:

• To evaluate the efficacy, safety, and quality of life (QoL) improvements associated with oral immunotherapy (OIT) for food allergies.
• To assess OIT's potential as a therapeutic option for managing food allergies and their psychosocial impacts.

Main Methods:

• Review of clinical trials and meta-analyses investigating oral immunotherapy (OIT) for food allergies.
• Analysis of OIT's impact on allergic reactivity thresholds, immune responses, and adverse events (AEs).

Main Results:

• OIT effectively increases tolerance to peanuts and other foods, demonstrating measurable serum immune responses.
• OIT-related adverse events are common but serious reactions are rare, with most patients continuing treatment.
• The majority of participants report improved quality of life and a positive outlook on OIT.

Conclusions:

• Oral immunotherapy (OIT) shows significant promise as a therapeutic strategy for food allergies, improving tolerance and psychosocial well-being.
• Further research is needed to optimize OIT regimens for sustained protection and regular food consumption.
• Shared decision-making between patients and healthcare providers is crucial for effective OIT implementation.